Clinical Trial Update: Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Stapokibart Injection for moderate to severe Bullous Pemphigoid is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Stapokibart Injection (Stapokibart)

Snippet

Sponsor: Chengdu Kangnuoxing Biopharma,Inc. | Conditions: Bullous Pemphigoid (BP) | Phase 3 | Status: NOT_YET_RECRUITING